<DOC>
	<DOCNO>NCT02717195</DOCNO>
	<brief_summary>To evaluate efficacy 10 20 mg/day Lu AF35700 schizophrenia symptom patient treatment-resistant schizophrenia ( TRS )</brief_summary>
	<brief_title>Effect Lu AF35700 Patients With Treatment-resistant Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>The patient schizophrenia , diagnose accord DSM5 ( TM ) ( Diagnostic Statistical Manual Mental Disorders ) confirm Mini International Neuropsychiatric Interview Schizophrenia Psychotic Disorders The patient either inpatient psychiatric set outpatient consult psychiatrist . Patients treated adequate dose ( ) agent ( ) antipsychotic treatment least 2 week prior Screening The patient fail show adequate response level psychotic symptom despite least one document treatment trial adequate dose antipsychotic agent prescribe adequate time ( least last 6 week ) 2 year prior Screening . The failure respond current antipsychotic treatment trial may consider retrospective failed treatment , patient treat 6 week adequate dose ( ) agent ( ) The patient PANSS total score ≥80 score ≥4 least 2 follow PANSS item ( Screening first visit Period A ) The patient CGIS score ≥4 Screening first visit Period A The patient current primary psychiatric disorder schizophrenia assess Mini International Neuropsychiatric Interview ( MINI ) The patient experience acute exacerbation his/her psychotic symptom The patient respond treatment clozapine Other protocol define inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>